[18F]Fluoride PET-CT in psoriasis patients at risk for developing psoriatic arthritis
Key facts
- Where
- Amsterdam, HollandiaSee the site
- Phase
- 2. fázis
Where in Hollandia
- Amsterdam UMC StichtingAmsterdam, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stichting Amsterdam UMC
- Trial code
- EU 2024-514759-13-01
- Record updated
- 2024. december 16.
- Original description
The primary objective of this proof-of-concept study is to investigate the feasibility of whole body [18F]Fluoride PET-CT scans to detect axial and peripheral new bone formation, in psoriasis patients that are at risk to develop clinically manifest psoriatic arthritis.Read full original descriptionShow less
The primary objective of this proof-of-concept study is to investigate the feasibility of whole body [18F]Fluoride PET-CT scans to detect axial and peripheral new bone formation, in psoriasis patients that are at risk to develop clinically manifest psoriatic arthritis.
Inclusion: Patients with a diagnosis of psoriasis and an age of 18 years or older; ≥1 arthralgia and/or enthesiopathy in ≥1 location(s) ≤ 1 year, not secondary to trauma; ≥1 of the following: Nail psoriasis, First-degree relative with PsA and/or BSA ≥3%.
Exclusion: Systemic therapy for psoriasis (DMARD, bDMARD); Treatment with study medication in the past 3 months; Other rheumatic disease (such as Axial SpA, RA, SLE, Sjögren); Osteoarthritis and/or mechanical explanation of the pain in joints and/or tendons; Clinically evident arthritis (and/or tenosynovitis); Pregnancy or breast-feeding.